The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these ...

The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to ...

In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...

A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas. When ...

Rezatapopt is a first-in-class oral therapy designed to target the TP53 Y220C mutation. This mutation affects the p53 protein ...

The study investigated r ezatapopt (PC14586), a first-in-class small molecule designed to selectively bind and reactivate the ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...